在异脂蛋白E和阿尔茨海默病病理学跨祖先的性别差异
Xiaoyi Xu1,2, Jiseon Kwon1,3, Ruiqi Yan1,2
1NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, Missouri.
JAMA network open
|March 11, 2025
概括
在阿波利波蛋白E (APOE) -ε4等位基因.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物标志物 生物标志物
背景情况:
- 年龄,性别和阿波利波蛋白E (APOE) 是阿尔茨海默病 (AD) 的关键风险因素.
- APOE对阿尔茨海默病的影响因性别和祖先而异.
- 以前的研究还没有系统地检查大脑脊髓液 (CSF) AD生物标志物的性别和祖先相互作用.
研究的目的:
- 为了研究性别,APOE-ε4和核心CSFAD生物标志物 (Aβ42,p-tau,总tau) 之间的关联.
- 分析这些跨不同祖先群体的关联.
主要方法:
- 一项队列研究涉及20个队列中的4592名参与者.
- 参与者被分为非洲,亚洲和欧洲祖先.
- 统计分析评估了性别,APOE-ε4剂量和CSF生物标志物水平之间的关联,并进行了跨祖先的元分析.
主要成果:
- 在两性中,较高的APOE-ε4剂量与较低的Aβ42水平相关.
- 在欧洲血统的男性中,APOE-ε4和Aβ42之间的关联比欧洲血统的女性更强.
- 女性的p-tau和总tau水平较高,APOE-ε4与tau病理的关联在女性中更为明显,特别是在非洲和欧洲祖先中.
结论:
- APOE-ε4等位基因与陶积累的关联在女性中比男性更大.
- 对APOE-ε4对AD生物标志物和tau病理的影响的性别差异至关重要.
- 需要进一步的研究才能充分阐明祖先特有的差异.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.7K
相关概念视频
Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142
